Week in Review: Beijing's BeiGene Raises $185 Million for Clinical Trial Program

BeiGene completed a $200 secondary offering (including $15 million from selling shareholders) that will support global clinical trials of four novel drugs; Taikang Insurance paid $169 million to acquire 26% of China hospital operator Harmonicare; Shenzhen Hepalink invested $36.5 million in Kymab, a British  novel mAb company; Beijing Tinavi Medical paid $1.5 million for China rights to spinal implants from France's Spineway; WuXi Biologics signed an MOU to create a manufacturing partnership with Prima Biomed of Australia for Prima's oncology drug candidate; Elanix Biotech of Germany and Oxford MEStar announced a LOI for a JV to market Elanix's GynRepair in China; and Yisheng Biopharma of Beijing completed a Phase I trial of its novel PIKA hepatitis B vaccine. More details.... Stock Symbols: (NSDQ: BGNE) (HK: 1509) (SHZ: 002399) (ASX: PRR; NSDQ: PRMD) (SX: ELN) Share this with colleagues: // //